NasdaqGM:KALVBiotechs
Chiesi Deal Shapes KalVista Shareholder Outlook And Valuation Potential
Chiesi Farmaceutici S.p.A. has entered into a definitive agreement to acquire KalVista Pharmaceuticals (NasdaqGM:KALV).
The deal includes a tender offer followed by a merger process, with completion subject to specified closing conditions.
Responsibility for EKTERLY®, a treatment for hereditary angioedema (HAE), is set to move from KalVista to Chiesi once the transaction is finalized.
KalVista focuses on treatments for hereditary angioedema, and EKTERLY® is a key product in that portfolio...